# Marginal zone lymphomas: ESMO clinical practice guidelines

Source: https://onco.cc/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/  
OnCo record `paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The ESMO guideline for marginal zone lymphomas sets out the treatment of gastric and non-gastric extranodal, splenic and nodal forms, including antibiotic eradication, low-dose radiotherapy, watch and wait, rituximab-based therapy and BTK inhibitors at relapse.

## Summary

Evidence-based guideline covering diagnosis, staging, and first-line and relapsed treatment of extranodal (MALT), splenic and nodal marginal zone lymphomas, including the role of infectious agents (Helicobacter pylori, hepatitis C), involved-site radiotherapy, chemoimmunotherapy and novel agents.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Annals of Oncology
- Year: 2020
- DOI: 10.1016/j.annonc.2019.10.010
- Authors: Zucca E, Arcaini L, Buske C, et al.
- What it means: The site-specific and stage-specific approach on the marginal zone lymphoma page follows this guideline.
- Caveats: Randomised evidence is limited for most decisions in these indolent lymphomas.

## Sources

- Ann Oncol 2020: https://doi.org/10.1016/j.annonc.2019.10.010
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31912792/

## Connected records

- cancers: [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/)
- journals: [Annals of Oncology](https://onco.cc/journals/annals-of-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020.json